Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, U.S. Phase III trial (S0232) in 198 newly diagnosed MM patients, the overall response rate was 85.3%
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury